This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

20 Sep 2021

Catalent and Phathom Pharmaceuticals strike commercial supply agreement

The CDMO will provide commercial manufacturing and packaging services for Phathom's novel, orally active P-CAB

Phathom Pharmaceuticals, a late clinical-stage biopharmaceutical company focused on developing and commercialising novel treatments for gastrointestinal disease, has secured Catalent's agreement for the commercial supply of its lead compound, vonoprazan.

Phathom's lead compound, which is currently in late clinical-stage development for the treatment of gastric acid-related diseases and disorders, is a novel, orally active potassium-competitive acid blocker (P-CAB). P-CABs are a new class of medicines that block acid secretion in the stomach.

Should vonoprazan receive FDA approval, Catalent will provide the commercial manufacturing and packaging of the product at its premier site for complex oral drug formulation and large-scale oral solid dose manufacturing in Winchester, Kentucky.

In 2015, the CDMO doubled the site's footprint to 180,000 sq. ft, and in 2019 undertook a $40-million investment that saw the installation of new equipment to increase its tablet and capsule manufacturing capabilities.

Dr Aris Gennadios, President, Softgel & Oral Technologies, Catalent described the agreement between the two companies as "the start of long-term partnership".

Phathom has the rights for the development and commercialization of vonoprazan in the US, Europe, and Canada.

Related News